https://wnbfactory.com/images/totoslot138/ https://wnbfactory.com/images/slot303/ https://wnbfactory.com/images/totoslot4d/
Drug Innovation – Page 4 – Pacific Research Institute

Drug Innovation

Commentary

Bipartisan Price Transparency Reforms Will Improve Outcomes

Beneficial healthcare change is occurring – in a bipartisan manner too. The reform, referred to as the Transparency in Coverage (Tic) rule, improves the functioning of the healthcare market; and unlike the calls for price controls or increased government distortions, improving the efficiency of the healthcare market can achieve the ...
Commentary

PBM Industry Shadowy, Congress Shines Much Needed Light

The last few months have seen a flurry of activity on Capitol Hill regarding prescription drug reform, with a particular focus on pharmacy benefit managers, or PBMs. The U.S. Senate Finance Committee is set to markup a bipartisan PBM reform bill within the next few days. The House Energy and Commerce ...
Commentary

Imposing Price Controls Is Never The Answer

The Senate Health, Education, Labor, and Pensions (HELP) Committee is currently reauthorizing the Pandemic and All-Hazards Preparedness Act (PAHPA), which is supposed to help us prepare for the next public health emergency. Never missing an opportunity to impose price controls on anything and everything, Senator Bernie Sanders (I-VT) wants to ...
Commentary

Democrats want to take medicinal price controls further

Senate Democrats Take One More Step Toward Socialized Medicine

It’s been less than a year since Democrats enacted the Inflation Reduction Act, which gives Medicare the power to set the prices of certain medicines. Those price controls have yet to go into effect. But Democrats already want more. They’ve introduced new legislation that would amp up those price controls ...
Commentary

There is a new Senate bill that targets PBMs

Break the Grip of Pharmacy Benefit Managers

A new Senate bill takes aim at one of the chief drivers of the high out-of-pocket drug costs that many consumers are experiencing — middlemen known as “pharmacy benefit managers.” Introduced in mid-June by a bipartisan group of senators including Finance Committee Chair Ron Wyden, D-Ore., and Ranking Member Mike Crapo, R-Idaho, ...
Commentary

Read the latest on drug price controls

Dems’ Drug Price Controls Would Mean Fewer Drugs And Fewer Jobs

Hundreds of lifesaving therapies will never be invented, and as many as 1.1 million jobs will be lost if Senate Democrats successfully expand their prescription drug price-fixing program, according to a major new study. The study, conducted by the research group Vital Transformation, modeled the effects of the SMART Prices Act. Sponsored ...
Drug Innovation

NEW BRIEF: Cash-Based Support Would Empower Vulnerable to Buy Private Health Insurance, Create More Effective Safety Net

Click to download the brief “Tens of millions are stuck in a flawed government-run healthcare system that provides sub-par care to patients, imposes huge taxpayer costs, and harms the broader healthcare system,” said Dr. Wayne Winegarden, director of PRI’s Center for Medical Economics and the series author. “By providing cash-based ...
Commentary

Read the latest on the Inflation Reduction Act's drug pricing reforms

Merck Fighting for Rights, Market-based Health Care

Pharmaceutical giant Merck announced last week that it is taking the federal government to court over the Inflation Reduction Act’s drug pricing reforms. The lawsuit alleges that the law’s Medicare price negotiation program violates some of the most fundamental rights guaranteed by the U.S. Constitution. “This is not ‘negotiation,'” the company says ...
Commentary

New COVID-19 research is troubling

Gov’t Undermines Search for Heart Disease Treatments

New research into COVID-19 has revealed some troubling findings. Even mild cases can lead to lasting heart complications. Comparing test data collected before and after a group of patients in their mid-30s contracted mild cases of COVID, researchers noticed an increase in arterial stiffness and cardiovascular inflammation. That means they may face “a widespread ...
Commentary

Moderna, Pfizer signal they plan to raise price of their shots

In defense of pandemic profits

The price of a COVID-19 shot will soon go up. The federal public health emergency ended this month, and the government will stop providing COVID vaccines to all Americans free of charge. Moderna and Pfizer have both signaled that they plan to raise the prices of their shots once the ...
Commentary

Bipartisan Price Transparency Reforms Will Improve Outcomes

Beneficial healthcare change is occurring – in a bipartisan manner too. The reform, referred to as the Transparency in Coverage (Tic) rule, improves the functioning of the healthcare market; and unlike the calls for price controls or increased government distortions, improving the efficiency of the healthcare market can achieve the ...
Commentary

PBM Industry Shadowy, Congress Shines Much Needed Light

The last few months have seen a flurry of activity on Capitol Hill regarding prescription drug reform, with a particular focus on pharmacy benefit managers, or PBMs. The U.S. Senate Finance Committee is set to markup a bipartisan PBM reform bill within the next few days. The House Energy and Commerce ...
Commentary

Imposing Price Controls Is Never The Answer

The Senate Health, Education, Labor, and Pensions (HELP) Committee is currently reauthorizing the Pandemic and All-Hazards Preparedness Act (PAHPA), which is supposed to help us prepare for the next public health emergency. Never missing an opportunity to impose price controls on anything and everything, Senator Bernie Sanders (I-VT) wants to ...
Commentary

Democrats want to take medicinal price controls further

Senate Democrats Take One More Step Toward Socialized Medicine

It’s been less than a year since Democrats enacted the Inflation Reduction Act, which gives Medicare the power to set the prices of certain medicines. Those price controls have yet to go into effect. But Democrats already want more. They’ve introduced new legislation that would amp up those price controls ...
Commentary

There is a new Senate bill that targets PBMs

Break the Grip of Pharmacy Benefit Managers

A new Senate bill takes aim at one of the chief drivers of the high out-of-pocket drug costs that many consumers are experiencing — middlemen known as “pharmacy benefit managers.” Introduced in mid-June by a bipartisan group of senators including Finance Committee Chair Ron Wyden, D-Ore., and Ranking Member Mike Crapo, R-Idaho, ...
Commentary

Read the latest on drug price controls

Dems’ Drug Price Controls Would Mean Fewer Drugs And Fewer Jobs

Hundreds of lifesaving therapies will never be invented, and as many as 1.1 million jobs will be lost if Senate Democrats successfully expand their prescription drug price-fixing program, according to a major new study. The study, conducted by the research group Vital Transformation, modeled the effects of the SMART Prices Act. Sponsored ...
Drug Innovation

NEW BRIEF: Cash-Based Support Would Empower Vulnerable to Buy Private Health Insurance, Create More Effective Safety Net

Click to download the brief “Tens of millions are stuck in a flawed government-run healthcare system that provides sub-par care to patients, imposes huge taxpayer costs, and harms the broader healthcare system,” said Dr. Wayne Winegarden, director of PRI’s Center for Medical Economics and the series author. “By providing cash-based ...
Commentary

Read the latest on the Inflation Reduction Act's drug pricing reforms

Merck Fighting for Rights, Market-based Health Care

Pharmaceutical giant Merck announced last week that it is taking the federal government to court over the Inflation Reduction Act’s drug pricing reforms. The lawsuit alleges that the law’s Medicare price negotiation program violates some of the most fundamental rights guaranteed by the U.S. Constitution. “This is not ‘negotiation,'” the company says ...
Commentary

New COVID-19 research is troubling

Gov’t Undermines Search for Heart Disease Treatments

New research into COVID-19 has revealed some troubling findings. Even mild cases can lead to lasting heart complications. Comparing test data collected before and after a group of patients in their mid-30s contracted mild cases of COVID, researchers noticed an increase in arterial stiffness and cardiovascular inflammation. That means they may face “a widespread ...
Commentary

Moderna, Pfizer signal they plan to raise price of their shots

In defense of pandemic profits

The price of a COVID-19 shot will soon go up. The federal public health emergency ended this month, and the government will stop providing COVID vaccines to all Americans free of charge. Moderna and Pfizer have both signaled that they plan to raise the prices of their shots once the ...
Scroll to Top